Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 10/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 8/20 | 0.38 |
| ▸ | ACLY | P53396 | 3/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599413 | 0.86 | BRD4 (0.40) | FABP4FABP5SLC16A3BRD4 | |
| SCHEMBL17613353 | 0.81 | FABP4 (0.38) | FABP4PTK2BSMN1; SMN2FABP5ACLY | |
| SCHEMBL17599355 | 0.80 | PTK2B (0.43) | FABP4PTK2BSMN1; SMN2FABP5ACLY | |
| SCHEMBL17599385 | 0.79 | TSHR (0.47) | FABP4PTK2BSMN1; SMN2FABP5ACLY | |
| SCHEMBL17599412 | 0.78 | FABP4 (0.45) | FABP4PTK2BSMN1; SMN2FABP5ACLY | |
| SCHEMBL17599408 | 0.78 | BRD4 (0.36) | SLC16A3BRD4 | |
| SCHEMBL17599305 | 0.77 | ACLY (0.55) | FABP4PTK2BSMN1; SMN2FABP5ACLY | |
| SCHEMBL17599320 | 0.76 | SMN1; SMN2 (0.54) | FABP4PTK2BSMN1; SMN2ACLYSLC16A3 | |
| SCHEMBL17599333 | 0.75 | PTK2B (0.52) | FABP4PTK2BSMN1; SMN2FABP5ACLY | |
| SCHEMBL17599392 | 0.75 | CCKBR (0.47) | FABP4PTK2BSMN1; SMN2FABP5ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |